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Polo-like kinase 1 (Plk1) is one of the major kinases controlling mitosis and cell division.
Plk1 is first recruited to the centrosome in S phase, then appears on the kinetochores
in late G2, and at the end of mitosis, it translocates to the central spindle. Activation of
Plk1 requires phosphorylation of T210 by Aurora A, an event that critically depends on
the co-factor Bora. However, conflicting reports exist as to where Plk1 is first activated.
Phosphorylation of T210 is first observed at the centrosomes, but kinase activity seems
to be restricted to the nucleus in the earlier phases of G2. Here, we demonstrate that
Plk1 activity manifests itself first in the nucleus using a nuclear FRET-based biosensor
for Plk1 activity. However, we find that Bora is restricted to the cytoplasm and that
Plk1 is phosphorylated on T210 at the centrosomes. Our data demonstrate that while
Plk1 activation occurs on centrosomes, downstream target phosphorylation by Plk1 first
occurs in the nucleus. We discuss several explanations for this surprising separation of
activation and function.
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Introduction
Polo-like kinase 1 (Plk1) is an important kinase during the cell cycle. It controls several key processes
that drive cells into and through mitosis such as centrosome maturation, spindle assembly, sister
chromatid cohesion, cytokinesis, and recovery from a DNA damage-induced arrest (1). To carry
out these specific functions, Plk1 is recruited to very specific subcellular sites throughout the
cell cycle. Plk1 is predominantly localized at the centrosomes during S-phase, G2, and mitosis.
In addition, Plk1 localizes to the kinetochores during G2 and mitosis and at the end of mitosis
when the chromosomes segregate Plk1 translocates to the spindle midzone (2). This localization
of Plk1 depends on its Polo-box domain that can efficiently bind to pre-phosphorylated substrates
(3, 4) and can target Plk1 to its various subcellular localizations in the cell (5–9). Plk1 is first
activated in G2, by phosphorylation on its T210-residue (10). The Aurora A kinase is responsible
for this phosphorylation event and requires binding of the co-factor Bora in order to be able to
phosphorylate Plk1 (11, 12). The notion that Plk1 is activated in G2 is well established; however, the
exact location in the cell where Aurora A phosphorylates Plk1 is not clear. Both proteins localize
to centrosomes and T210-phosphorylated Plk1 has also been observed at centrosomes (1, 12, 13).
However, antibodies targeting T210-phosphorylated Plk1 have been shown to recognize off-target
epitopes, making analysis based on these signals ambiguous (14). In addition, measuring Plk1
activity in living cells using a FRET-based biosensor specifically regulated by Plk1 showed that
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substrate phosphorylation by Plk1 activity is first observed in the
nucleus at around 5 h before mitosis, when S-phase is completed,
with activity spreading to the cytoplasm approximately 2 h before
mitosis (12, 15). A straightforward interpretation of this observa-
tion is complicated by the fact that the FRET-based biosensor is
diffusible and active transportation of the FRET-based biosensor
could contribute to the observed effects. Moreover, the localiza-
tion of the co-factor Bora is not extensively studied. InDrosophila,
where Bora was first identified as a co-factor for Aurora A, it
was shown that Bora is located in the nucleus and translocates
to the cytoplasm in early prophase (16). However, localization
of Bora during the cell cycle in human cells seems to be reg-
ulated differently, although this is mainly based on exogenous
Bora (17).
Here we show, using a nuclear localized FRET-based biosen-
sor, that initial substrate phosphorylation by Plk1 in the nucleus
is not the result of a diffusing FRET-probe, but that substrate
phosphorylation by Plk1 initially occurs in the nucleus. How-
ever, we find that sequestration of Plk1 in the nucleus prevents
phosphorylation of T210. This is in contrast to sequestration
of Plk1 to the centrosomes, where Plk1 can get phosphorylated
on T210. Thus, our data show that Plk1 is phosphorylated and
activated at the centrosome, but Plk1 activity is first seen to rise
in the nucleus. We were unable to reconstitute Plk1 function by
mutants of Plk1 that strictly localized at the centrosomes or in
the nucleus, indicating that Plk1 needs to be able to diffuse from
the centrosomes to the nucleus in order to be fully functional.
Finally, we show that Bora localizes strictly in the cytoplasm in
human cells and Bora degradation is induced approximately 2 h
before cells enter mitosis. This degradation does not completely
remove all Bora, as we have shown previously, and Bora/Aurora A
continue to activate Plk1 also in mitosis (14, 17). Taken together,
our data show that Plk1 is activated in the cytoplasm where
both Bora and Aurora A are localized; however, translocation
of Plk1 to the nucleus seems to be required for the establish-
ment of target phosphorylation, as it is where Plk1 activity first
appears.
Materials and Methods
Cell Culture, Antibodies, and Reagents
Human osteosarcoma U2OS cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco) supplemented with
6% FCS (Lonza), 2mM -glutamine, 100U/ml penicillin, and
100mg/ml streptomycin. Cell lines expressing LAP-Plk1, AKAP-
LAP-Plk1, H2B-LAP-Plk1, and GFP-Bora under the control of
tetracycline-inducible were cultured in DMEM containing Tet
system approved fetal bovine serum (Lonza). Antibodies that were
used were directed against Plk1 (18, 19), Plk1, Cyclin B1, Actin
(all from Santa Cruz), GFP (Roche), Plk1-pT210 (BD), Tubulin
(Sigma), Bora (17), Aurora A (Cell Signaling) Histone H3-pS10,
andH2AX (both fromUpstate). The following drugswere used: BI
2536 (100 nM, Boehringer Ingelheim Pharma), MLN8054 (1µM,
Millennium Pharmaceuticals), thymidine (2.5mM, Sigma), caf-
feine (5mM, Sigma), adriamycin (0.5µM, Sigma), nocodazole
(250 ng/ml, Sigma), PI (Sigma) puromycin (Sigma, 2µg/ml), and
tetracyclin (Sigma, 1µg/ml).
Cloning and Generation of Stable Cell Lines
H2B-tagged versions of LAP-Plk1 and the FRET-based biosensor
were generated in the following manner: H2B was amplified
by PCR using the forward primer 50-AAGCTTATGCCAGA
GCCAGCGAAGTC-30 and the reverse primer 50-AAGCTTAG
ATCCTTAGCGCTGGTGTACTTGG-30 and ligated into either
the FRET-based biosensor or the LAP-Plk1 construct using
the restriction enzyme HindIII (NEB). AKAP-LAP-Plk1 was
generated in the following manner: the AKAP centrosomal
binding doamina was amplified by PCR using the forward
primer 50-AAGCTTGCCACCATGGCCAACATTGAAGCC-30
and the reverse primer 50-CTTAAGCTTCTCATGCCAGCATG
AAATTG-30 and ligated into the LAP-Plk1 consruct using the
restriction enzymes HindIII and EcoRI (NEB). The pTON-GFP-
Bora construct has been described previously (12). U2OS-derived
U2TR cells stably expressing LAP-Plk1 have been described
previously (12). U2TR cells stably expressing AKAP-LAP-Plk1,
H2B-LAP-Plk1, and GFP-Bora were generated by calcium
phosphate transfection of the constructs, selection of stable clones
by zeocin (400mg/ml, Invitrogen) treatment for 2weeks followed
by clonal selection. Stable clones were grown in media containing
tetracycline system approved fetal bovine serum (Lonza). To
induce expression, cells were treated for indicated times with
tetracycline (1mg/ml).
Transfections, Cell Synchronization, and FACS
Cells were transfected using calcium phosphate transfection of
plasmids. For selection of transfected cells with pSuper constructs,
GFP-spectrin was co-transfected for FACS or with pBABE-puro
followed by puromycin treatment for western blot analysis. For
analysis of checkpoint recovery, cells were synchronized at the
G1/S-border by thymidine (2.5mM) for 24 h followed by a 6 h
release and 1 h incubation with Adriamycin (0.5µM). Afterwards,
cells were kept for 16 h in nocodazole (250 ng/ml). Recovery was
induced by adding caffeine (5mM). Unperturbed mitotic entry
was assayed by a 24 h thymidine block followed by a release into
nocodazole. For reconstitution assays, expression was induced by
addition of tetracycline (1mg/ml) at the indicated times. For FACS
analysis, cells were transfected were harvested by trypsinization
and fixed with ice-cold 70% ethanol. Cells were stained using
the anti-Histone H3-pS10 antibodies (Millipore) and Alexa488-
conjugated secondary antibodies (Molecular Probes). DNA was
stained using propidium iodide and samples were analyzed on a
FACSCalibur flow cytometer (BD biosciences). Cell cycle distri-
bution was determined by flow cytometry counting 104 events of
cells positive for GFP-spectrin.
FRET- and Live Cell Imaging
For time-lapse microscopy, cells were grown on LabTek II
chambered coverglasses in Leibovitz’s L-15 medium (Gibco) sup-
plemented with 6% FCS (Lonza), 2mM -glutamine, 100U/ml
penicillin, and 100mg/ml streptomycin, and were imaged with
DIC on a Zeiss Axiovert 200M using 20 0.75NA objectives or
on a Deltavision imaging system using 20 0.75NA objectives.
Images were taken every 20min. GFP-Bora levels were quantified
by measuring the integrated density of the GFP signal in cells.
Background was subtracted using an area that contained no cells.
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The FRET-based biosensor formonitoring PLK1 activity has been
described previously (12, 20). The CFP/YFP emission ratio after
CFP excitation of U2OS cells stably expressing the FRET-based
biosensor was monitored on a Deltavision Elite imaging sys-
tem, using a 20 0.75NA objective. Images were acquired every
20min. The images were processed with ImageJ using the Ratio
Plus plug-in (http://rsb.info.nih.gov/ij/).
Cellular Fractionation Immunoprecipitations and
Western Blotting
Chromatin fractionationwas performed as described (21). Soluble
cytosolic proteins were extracted from U2OS cells by incubating
cells in buffer A (10mm HEPES, pH 7.9, 10mm KCl, 1.5mm
MgCl2, 0.34M sucrose, 10% glycerol, 1mm DTT, 0.1% Triton
X-100, and protease inhibitor cocktail) at 4°C for 10min and
spinning down at 1500 g for 2min. Soluble nuclear fraction was
obtained by extraction of pelleted nuclei with an equal amount
of buffer B (10mm HEPES, pH 7.9, 3mm EDTA, 0.2mm EGTA,
1mm DTT) and spinning down at 2000 g for 2min. Insoluble
chromatin was washed with buffer B and finally resuspended in
SDS sample buffer. For immunoprecipitations, cells were lysed in
with 1ml lysis buffer (1% NP-40, 50mM Hepes pH 7.4, 150mM
NaCl, 1mM EGTA, 1mM MgCl2, 1mM NaF, 1mM Na3VO4,
25mM β-glycerophophatese, 1 tablet of complete EDTA-free per
50ml) on ice for 10min. The lysate was cleared by centrifugation
and 10% of supernatant was used for whole cell lysate. Immuno-
precipitations were performed using S-protein beads (Novagen)
or with antibodies bound to Dynabeads Protein A (Life Technolo-
gies). Beads were washed with TBST and incubated with the rest
of the lysate at 4°C for 24 h. Beads were washed extensively with
lysis buffer, after which bound protein was eluted with Laemmli
sample buffer.
Results
The Plk1 FRET-Probe Is Phosphorylated in the
Nucleus
Plk1 localizes both at the centrosomes and kinetochores during
G2. While most of the literature suggests that Plk1 is activated
at the centrosomes, this is mainly based on immunofluoresence
using anti-phospho-T210 antibodies (12), and the fact that Aurora
A is localized at the centrosomes in G2 (13). However, using
a FRET-based biosensor to measure the Plk1 activity in real-
time, we found that Plk1 activation is first visible in the nucleus
approximately 5 h before cells entered mitosis [Figure 1A; (12)].
Since this probe is not tethered, we wondered whether shuttling
of an activated probe between the cytoplasm and the nucleus
might account for this observation. To test this, we generated
an H2B-tagged FRET-based biosensor for Plk1 that is localized
exclusively in the nucleus (Figure 1B). We observed that cells
expressing this construct entered mitosis normally and displayed
similar kinetics of Plk1 activation in the nucleus (Figures 1C,D).
In addition, pharmacological inhibition of Plk1 with the small
molecule inhibitor BI 2536 (22) led in both cases to inhibition of
Plk1 activity, except for a small signal in mitosis (Figures 1A–D),
which we have previously shown to be dependent on the mitotic
kinase Mps1 (14). In addition, inhibition of Aurora A with the
small molecule inhibitor MLN 8054 (23) also led to similar kinet-
ics of Plk1 activation where the initial activation is repressed
(Figures 1A–D). Activation of Plk1 during the later stages of
G2 is also dependent on Aurora A, but inhibition of Aurora A
through MLN 8054 is not penetrant enough to achieve complete
inhibition of its activity, as we have shown previously (14). Taken
together, these results show that immobilization of the FRET-
based biosensor for Plk1 does not affect the timing of its phospho-
rylation, demonstrating that substrate phosphorylation by Plk1
first becomes apparent in the nucleus, approximately 5 h before
cells enter mitosis.
Dynamic Localization of Plk1 is Important for
Checkpoint Recovery
Since substrate phosphorylation by Plk1 is first observed in the
nucleus during G2, we next asked if Plk1 needs to be on the
centrosomes or in the nucleus in order to promote entry into
mitosis during recovery from a DNA damage-induced arrest. To
this end, we generated stable cell lines expressing tetracycline-
inducible and RNAi-resistant variants of Plk1 that were either
freely diffusible, or exclusively localized at centrosome or in the
nucleus. For this purpose, we used EGFP-TEV-S (LAP)-tagged
wild-type Plk1 (12, 24), an AKAP-LAP-Plk1 fusion that is phys-
ically tethered to the centrosome through fusion to the centro-
somal targeting domain of AKAP450 (25) and an H2B-LAP-Plk1
fusion in which Plk1 is fused to H2B and is therefore located
exclusively in the nucleus (Figure 2A). Using a short hairpin that
targets endogenous Plk1 (26), we depleted the endogenous pro-
tein and used tetracycline-induced expression of the exogenous
proteins for protein replacement (Figure 2B). We first analyzed
if these fusion proteins could be phosphorylated at T210 during
checkpoint recovery. To this end, we synchronized the cells in G2
and induced DNA damage by Adriamycin. As a consequence of
checkpoint activation, these cells remain arrested in G2, and we
subsequently induced checkpoint recovery by adding caffeine for
8 h. During this time, Plk1 gets activated through phosphorylation
of T210 and cells resume the cell cycle and enter mitosis (12,
26). Indeed, LAP-Plk1 was efficiently phosphorylated at T210
after the addition of caffeine (Figure 2C). In accordance with
the hypothesis that Plk1 is activated at centrosomes, we found
that AKAP-LAP-Plk1 was also phosphorylated at T210. Although
the phosphorylation of AKAP-LAP-Plk1 was less prominent than
LAP-Plk1, we could not detect any phosphorylation of T210 on
H2B-LAP-Plk1, suggesting that activation of Plk1 occurs outside
of the nucleus (Figure 2C). Furthermore, inhibition of Aurora
A affected phosphorylation of Plk1 at T210 in both LAP-Plk1
as well as LAP-AKAP-Plk1 showing that this phosphorylation
is dependent on Aurora A (Figure 2D). Next, we wondered if
the centrosomal- and nuclear-tethered Plk1 versions could induce
checkpoint recovery, a well-established function of Plk1 (12, 26).
To this end, we depleted endogenous Plk1 by RNAi and recon-
stituted Plk1 expression with the exogenous proteins prior to
induction of recovery. We subsequently determined the amount
of mitotic cells after 8 h of caffeine treatment as a measure of
checkpoint recovery. Expression of the exogenous versions of
Plk1 did not affect recovery in the presence of the endogenous
Plk1 and we clearly observed a reduction in cells entering mitosis
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FIGURE 1 | Plk1 activity is first seen in the nucleus. (A) Stills from a movie
showing false color-coded CFP/YFP emission ratios. The stills show control-, BI
2536-, and MLN 8054-treated U2OS cells expressing the diffusible FRET-based
biosensor for Plk1 activity while entering mitosis. BI 2536 was used at a
concentration of 100 nM; MLN 8054 at a concentration of 1µM. (B) Stills from a
movie showing false color-coded CFP/YFP emission ratios of U2OS cells
expressing the H2B-tagged FRET based biosensor were treated as in (A).
(C) Quantification of CFP/YFP-ratio of cells shown in (A). Error bars represent
the SD of 10 individual cells. (D) Quantification of CFP/YFP-ratio of cells shown
in (B). Error bars represent the SD of 10 individual cells; *p<0.0001.
when Plk1 was depleted (Figure 2E). Reconstitution of LAP-Plk1
rescued recovery, albeit not completely (Figure 2E). However,
reconstitution of AKAP-LAP-Plk1 or H2B-LAP-Plk1 was unable
to significantly increase the fraction of cells that could recover
(Figure 2D). These results indicate that Plk1 function requires free
diffusion of Plk1 between nucleus and cytoplasm, not only to be
efficiently phosphorylated at T210 but also to be able to promote
recovery from a DNA-damage-induced arrest.
Bora Localizes in the Cytoplasm
Activation of Plk1 is carried out by Aurora A, which phospho-
rylates T210 in G2. This phosphorylation event requires the
co-factor Bora (11, 12). To further study Plk1/Bora complex
formation, we synchronized cells at the G1/S border and per-
formed a time course. We immunoprecipitated Plk1 and analyzed
the amount of Bora that co-immunoprecipitated to see when
these proteins started to interact. We observed that interaction
between Plk1 and Bora occurs already early after thymidine
release, possibly reflecting Plk1 functions during replication (27),
while phosphorylation of Plk1 at T210 accumulates later in G2
(Figure 3A). Despite our best efforts, we were unable to detect any
Aurora A in these co-immunoprecipitation experiments, which
may indicate that the interaction of Aurora A with the Plk1-
Bora complex might be extremely transient (data not shown).
Since available antibodies that recognize Bora are not suitable
for immunofluorescence, we were unable to determine the exact
localization of endogenous Bora in cells (data not shown). There-
fore, we generated a tetracycline-inducible GFP-Bora cell line to
study Bora localization (17). Induction with tetracycline resulted
in efficient induction of GFP-Bora expression (Figure 3B). In
addition, GFP-Bora could efficiently co-immunoprecipitate Plk1
and this interaction increases when recovery is induced by the
addition of caffeine (Figure 3B). We next monitored the localiza-
tion of GFP-Bora. In Drosophila, Bora has been shown to initially
localize in the nucleus, then transfer to the cytoplasm in early
prophase until nuclear envelope breakdown (16). However, we
were unable to detect any substantial nuclear signal of GFP-Bora
in line with an earlier report (17); instead, we clearly observed
that Bora was persistently cytoplasmic throughout interphase.
When cells enter mitosis, Bora is targeted for degradation in a
Plk1- and βTrCP-dependent manner (17–19). To see if GFP-Bora
behaves in a similar manner, we filmed cells expressing GFP-
Bora entering mitosis. Indeed, we observed a reduction in GFP-
Bora expression approximately 2 h before cells entered mitosis,
similar to a recent report (Figures 3C,D) (17). In accordance
with the literature, degradation of Bora was abrogated when Plk1
was inhibited. In addition, inhibition of Aurora A had a similar
effect on the stability of Bora [Figures 3C,D; (17)], which is
consistent with the continuous activation of Plk1 by Aurora-A
during mitosis (14).
Because we were unable to monitor endogenous Bora by
immunofluorescence, we performed a fractionation assay to
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1324
Bruinsma et al. Spatial separation of Plk1 phosphorylation and activity
FIGURE 2 | Plk1 is activated at the centrosomes but needs to be
dynamically localized. (A) Expression of RNAi resistant LAP-Plk1,
AKAP-LAP-Plk1 or H2B-LAP-Plk1 was induced in U2TR stably expressing
these constructs by addition of tetracycline. DIC- and GFP-images were taken
of representative cells. (B) Tetracycline inducible U2TR cells stably expressing
RNAi resistant LAP-Plk1, AKAP-LAP-Plk1 or H2B-LAP-Plk1 were transfected
with an empty pSuper, or a pSuper targeting endogenous Plk1. Cells were
synchronized in G2 and damaged with 0.5µM adriamycin for 1 h and
expression was induced where indicated using tetracycline. 16 h after induction
of DNA damage cell were harvested and analyzed by western blotting.
(C) Tetracycline inducible U2TR cells stably expressing RNAi resistant LAP-Plk1,
AKAP-LAP-Plk1 or H2B-LAP-Plk1 were synchronized in G2 and damaged with
0.5µM adriamycin for 1 h and expression was induced where indicated using
tetracycline for 16 h. Cells were harvested at the indicated time points after
addition of caffeine and analyzed by western blotting. (D) Cells were treated as
in C. MLN 8054 was added at a concentration of 1µM either for 8 h together
with caffeine or during the last 4 h of caffeine. LAP-tagged proteins were
immunoprecipitated with S-protein agarose beads and analyzed by western
blot. (E) Tetracycline inducible U2TR cells stably expressing RNAi resistant
LAP-Plk1, AKAP-LAP-Plk1 or H2B-LAP-Plk1 were transfected with an empty
pSuper, or a pSuper targeting endogenous Plk1. Cells were synchronized in G2
and damaged with 0.5µM adriamycin for 1 h and expression was induced
where indicated using tetracycline. Cells were arrested for 16 h, recovery was
induced by caffeine addition for 8 h and the mitotic index was determined,
based on the percentage of Histone H3-pS10 positive cells, using FACS. Error
bars represent the SD of three independent experiments; *P<0.001.
separate cytoplasmic proteins from the nuclear proteins (21).
We synchronized cells in G2 and induced DNA damage. About
16 h after the DNA damaging insult, we induced recovery by
addition of caffeine and harvested cells after 1, 2, and 4 h to
monitor T210 phosphorylation. Similar to our observations with
the GFP-Bora-expressing cell line, endogenous Bora appeared to
be strictly cytoplasmic (Figure 3E). Interestingly, Aurora A was
clearly present in both the nucleus and the cytoplasm. Nuclear
enrichment of GFP-Aurora-A next to its well-known centro-
somal localization during G2 was also observed by monitor-
ing a GFP-Aurora A expressing U2OS cell during mitotic entry
(Figure 3F). Although the general idea is that Aurora A localizes
predominantly at the centrosomes, nuclear localization has also
been reported by overexpression studies as well as on endoge-
nous levels (15, 28). Phosphorylation of Plk1 at T210 did not
seem to be preferentially present in the cytoplasm or in the
nucleus as the signal appeared in both places at 4 h after caf-
feine addition. These results, combined with the data presented
in Figure 2, suggest that Plk1 is phosphorylated at T210 at the
centrosomes from where active Plk1 subsequently can translocate
to the nucleus.
Discussion
Plk1 localization is highly dynamic during the cell cycle. Acti-
vation starts in G2, presumably at the centrosomes, but activ-
ity monitored by a FRET-based biosensor is first observed in
the nucleus approximately 5 h before mitosis (12, 14). Simi-
larly, Plk1 localization to kinetochores, which depends on Plk1
activity, occurs at the S/G2 transition (15). These observations
raise questions about the exact location where Plk1 is initially
activated.
Here, we provide proof that stable phosphorylation of Plk1
targets first occurs in the nucleus. Since the H2B-tagged and
diffusible probes showed similar profiles, we ruled out the pos-
sibility that detection of Plk1 activity was affected by diffusion or
active import of the phosphorylated FRET-probe from the cyto-
plasm (Figure 1). This, in combination with our observation that
centrosome-tethered Plk1 is phosphorylated at T210 while H2B-
tethered Plk1 is not, implies that Plk1 needs to be in the cytoplasm
for its initial activation and subsequently move into the nucleus to
phosphorylate its targets. Neither the centrosome-tethered vari-
ant nor the nuclear-restricted variant of Plk1 is able to rescue
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FIGURE 3 | Bora localizes in the cytoplasm and is degraded 2h before
mitosis. (A) U2OS cells were synchronized at the G1/S border using a 24-h
thymidine block and harvested at the indicated times after thymidine release.
Plk1 was immunoprecipitated and protein levels were analyzed by western blot.
(B) Tetracycline inducible U2TR cells stably expressing GFP-Bora were
synchronized in G2, DNA damage was induced for 1 h using 0.5µM adriamycin.
Tetracycline was added where indicated and cells were arrested for 16 h.
Caffeine was added for 4 h where indicated. Cells were harvested and
GFP-Bora was immunoprecipitated. Protein levels were analyzed by western
blot. (C) Tetracycline inducible U2TR cells stably expressing GFP-Bora were
filmed asynchronously and expression was induced by tetracycline. Cells were
treated as indicated with 100 nM BI 2536 or 1µM MLN 8054. Stills from a movie
showing DIC- and GFP-images are shown of cells entering mitosis.
(D) Quantification of 3C, total GFP expression levels were measured over time.
Error bars represent SEM of 10 individually quantified cells. *p<0.0001.
(E) U2OS cells were arrested for 16 h after induction of DNA damage in G2 with
0.5µM adriamycin. Recovery was induced with caffeine for the indicated times.
Total lysates were obtained as well as cytoplasmic and chromatin fractions using
the cell fractionation protocol from Méndez and Stillman (21). (F) Stills from real
time imaging of a GFP-Aurora A-expressing U2OS cell entering mitosis.
recovery from a DNA damage-induced arrest in cells depleted
of endogenous Plk1 (Figure 2), further supporting a model in
which centrosomal activation is followed by translocation to the
nucleus in order for Plk1 to execute its function in regulating
mitotic entry. Finally, we show that Bora localizes exclusively in
the cytoplasm and its degradation is induced approximately 2 h
before cells enter mitosis. Our data suggest that Plk1 is phospho-
rylated at T210 at the centrosomes but phosphorylation of Plk1
targets is somehow inhibited in the cytoplasm, whereas activated
Plk1 that translocates to the nucleus can phosphorylate its targets
(Figure 4).
There are several possible explanations for the preferential
target phosphorylation by Plk1 in the nucleus. Phosphorylation of
the FRET-based biosensor can easily be reversed as Plk1 inhibition
decreases the CFP/YFP-ratio to basal levels in approximately half
an hour (14). This observation shows that phosphatases are also
at play and dephosphorylate the FRET-probe. Thus, preferential
substrate phosphorylation by Plk1 in the nucleus could either be
due to accumulation of active Plk1 to the nucleus or it could be
due to higher phosphatase activity directed toward Plk1 targets
in the cytoplasm. Our observation that the relative level of T210-
phosphorylation is similar in the cytoplasm compared to the
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FIGURE 4 | Spatial separation of Plk1 phosphorylation and activity.
Proposed model for Plk1 activation during G2. Plk1 binds to its co-factor
Bora and is subsequently activated at the centrosome on T210 by Aurora A.
Activity of the T210-phosphorylated Plk1 is inhibited in the cytoplasm,
possibly by Bora or by phosphatase activity directed at its substrates.
T210-phosphorylated Plk1 then translocates to the nucleus where the
inhibitory factors of Plk1 activity are absent and Plk1 starts phosphorylating its
substrates. The contribution of nuclear Aurora A is currently unclear. Yellow
and purple indicate high and low levels of Plk1 substrate phosphorylation,
respectively. Red arrows indicate phosphorylation events. The “P” indicates
phosphorylation of T210.
nucleus suggests that preferential substrate phosphorylation in
the nucleus is due to high phosphatase activity in the cytoplasm.
One of the candidate phosphatases that could suppress the activity
of Plk1 toward its cytoplasmic substrates is PP2A/B55 that is
highly active in cytoplasm until its inhibition by Greatwall kinase
and endosulfine shortly before mitotic entry (29–31). In addition,
PP2A/B55 has recently been shown to counteract Plk1 activity
through dephosphorylation of T210 after DNA damage (32).
We find that a version of Plk1 that is tethered to the centrosome
can be phosphorylated at T210, albeit less than the wild type
version of Plk1. However, it is not possible to functionally rescue
Plk1 function when Plk1 is tethered to the centrosome, something
others have observed as well (33). In addition, forced nuclear
localization did not result in phosphorylation at T210 during
recovery nor did it result in a functional rescue. These results
suggest that dynamic localization of Plk1 during the cell cycle
is of utmost importance to carry out its functions. Activity of
Plk1 can direct it to different subcellular sites. For instance, Plk1
is recruited in a Cdk-dependent manner to the centrosomes by
hCenexin1 (9) and to kinetochores by BubR1, Bub1, or INCENP
(8, 34, 35). In addition, Plk1 can also create its own docking site
to target itself to the kinetochores through PBIP1 (5) or mediate
its translocation to the central spindle in anaphase through PRC1
(7). These reports and our current results are clear indications that
dynamic localization of Plk1 is indispensible for proper execution
of its functions during G2 and mitosis.
Phosphorylation of Plk1 at T210 by Aurora A requires Bora
(11, 12). Our data strengthen the idea that initial phosphorylation
occurs at the centrosomes as we observe that Bora is strictly
cytoplasmic as opposed to phosphorylation in the nucleus. Bora
binds to the Plk1 Polo-box domain in a Cdk-dependent manner
(18). This not only allows Aurora A to phosphorylate Plk1 at
T210 but additionally targets Bora itself as a substrate of Plk1
(18, 19), since phosphorylation by Plk1 targets Bora for βTrCP-
dependent proteasomal degradation. While the literature so far
has suggested that this takes place in mitosis, we observed that
Bora levels already diminish at 2 h before cells enter mitosis (17).
This observation coincides roughly with the time that substrate
phosphorylation by Plk1 is first observed in the cytoplasm. Since
Boramost likely interactswith Plk1 in the cytoplasm, it is tempting
to speculate that despite the T210-phosphorylation that occurs in
the cytoplasm, Plk1 target phosphorylation is somehow inhibited
until Plk1 translocates to the nucleus where it cannot bind Bora
anymore (Figure 4). This could either take place by direct inhibi-
tion of phosphorylation by Plk1, or as mentioned earlier, by rapid
reversion of phosphorylation of Plk1 targets by a phosphatase
that is enriched in the cytoplasm. As the degradation of Bora
before mitotic entry coincides with Plk1 target phosphorylation
in the cytoplasm, it is a distinct possibility that Bora can func-
tion as an inhibitor of Plk1 activity, at least toward its other
substrates, in the cytoplasm. It would therefore be interesting
to test if binding of Bora to Plk1 can prevent efficient binding
to its other substrates, for example by occupying the Polo box
domain binding site. Further analysis of the Bora-Plk1 complex
and the effect of Bora-binding to Plk1-dependent phosphory-
lation of other Plk1 targets will be required to answer these
questions.
In addition to the downstream regulation, upstream regulation
of Aurora A activity during G2 and how this relates to specific
timing of T210-phosphorylation on Plk1 is currently unclear.
Aurora A relies on several co-factors to exert its functions and
we have previously shown that the Aurora A co-factor TPX2 does
not contribute to the activation of Plk1 during G2 and mitosis
(14). However, it will be interesting to investigate other Aurora
A co-activators and recruiters such as Ajuba (36) or CEP192
(37) and study their impact on timely activation of Plk1. More
detailed analysis of timing and activation events of Plk1, Bora, and
Aurora Awill be required to elucidate the complex spatiotemporal
regulation of Plk1 activation during G2.
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